Abstnct: Our objective was to obtain new information on the in vitro antilymphocytic action of the cytokine synthesis inhibitor FK 506 and the punne biosynthesis inhibitors mycophcnolic acid (MPA; the active mOlctv of RS6l443) and mizoribine (MZB) when used alone or in combination. When added at the initiation of six·day human mixed lymphocyte cultures (MLC). FK 506. MPA or MZB exhibited dose·dependent inhibition 01 T·lymphocvtc DNA synthesis. FK 506. however. was «Xl· fold more potent than MPA. and ((}IXlO·fold more potent than MZB. Combination of FK 506 with either MPA or MZB. each at suboptlonal concentrations. produced no more than additive inhibitory effects on 'H thvmldine Incorporation. Two-colour !low cytometnc analvsls 01 Iymphocvtes revealed that none of the drugs affected cell surface activatIOn molecule expressIOn (CD25 = IL·2R 55 kD lJ·chain. HLA·DR or CD71 = transferrin receptor ITRJ) on allosllmulated CD4' or CD!!' cells harvested at three days 01 culture. Bv day SIX. however. all three agents. at levels which markedly inhibited proliferation. suppressed the expression of activation markers on both CD4' and CD!!' cells. Also at day six. Inhibition 01 activation molecule expression on CD4' cells was achieved with the combination of FK 506 and either MPA or MZB at concentrations which. on their own. were ineffective. These data provide new. additional informallon on the in vitro antilymphocytic action of FK 506. MPA and MZB when used alone and in combinallon.
Introduction
The ctticacy and clinical pOlential of a variety of new im· munosuppressive drugs when used alone or in combinallon are currently the subjects of critical evaluation. superior therapeutic index to CsA both in transplantal1on~ II and autoimmune disease,"
Mycophenolic acid (MPA; the active moiety of RS· () 1443 = mycophenolate mofetil) and mizoribine (MZR) are strong inhibitors of enzymes which catalyse the de novo synthesis of guanine nucleotides that arc essenlIal for T cell replication. They thus act later in the cell cycle than FK 506.
By decreasing nucleotide availability. however. MPA and MZR may also inhibit signal transduction and the synthesis of cell surface proteins and receptors.II) .. 15 Effects 0/ drug combination on human MLR 147 Cultured mononuclear cells were washed and the expression of activation antigens was detected as described previously24 by staining cells with mC-conjugated anti-C025 (IL-2 receptor. a chain). anti-HLA-DR or anti-CD71 (TR) mouse IgG monoclonal antibodies and either phycoerythrin (PE)-conjugated anti-C04 or anti-CDS mouse monoclonal antibodies. All antibodies were from DAKO and were used at a final I : 10 dilution. mc-and PE-conjugated mouse IgO were used as background control. After washing, cells were fixed with 1 % wlv paraformaldehyde. followed by analysis in a FACSTAR flow cytometer (Becton-Dickinson, Rariton. NJ, USA). Five thousand cells were counted for each sample. Significances of differences between means were determined using Student's t-test.
Results
The influence of various concentrations of FK 506, MP A or MZB. added at the start of culture. on the uptake JH-TdR in six-day human MLC is shown in Figure I . Each drug exhibited a dose-related. inhibitory effect with maximal inhibition of DNA synthesis (85-97%) being achieved with 1.2 nM FK 506.0.3 f.l.M MPA and 386 f.l.M MZB. Combinations of moderately effective concentrations of FK 506 and either MPA or MZB produced no more than an additive inhibitory dfect on cell proliferation.
The effects of thc three immunosuppressive agents on human T cell surface IL-2R. HLA-DR and TR expression in three-and six-day MLC were examined by two-colour flow cytometric analysis. Cultures harvested after three days in the presence of FK 506. MPA or MZB showed no significant change in the incidence of CD4 + or CD8~ cells co-expressing any of the activation markers (data not shown). By day six. however. there were significant inhibitory effects of all three drugs on the incidence of both CD4' and CD8+ cells co-<.!xpressing each of the markers (Figure 2 ). At concentrations ()f each drug which gave maXimal inhibition of DNA syntheSIS ( Figure I) . but not at tenfold lower concentrations (which were moderately antiproliferativel. . .
• ' " was similar for both T cell subsets. although MZB was especially effective in suppressing CD8+ IL-2R expression (>80%). MZR was also the most effective agent and both MZR and MPA more effective than FK 506 in suppressing HLA-DR expression. Differences between the effects of these drugs. however. were not stastically significant. The incidence of CD4 + and CD8 + cells expressing TR was also inhibited (p < 0.02) by all three drugs and to a greater extent than IL-2R and HLA-DR. although as with the latter activation markers. at only the highest drug concentration tested.
Combinations of FK 506 and either MPA or MZB at concentraUons which. on their own caused only moderate Inhibition of DNA synthesis and no significant reducuon In cell surface marker expression. reduced the incidence of IL-2R·. HLA-DR'. and TR· cd Is ( Figure J ; data shown for FK 506-MZB combination only).
Discussion
In this study. we have shown that the immunosuppressive agents. FK 506. MPA (the active moiety of RS-61443) and MZB each has the capacity to profoundly inhibit T cell proliferatlon and the expression of T cell surface activation molecules following allostimulauon. In each instance. sigmfican! suppression of IL-2R (CD25; 55 kD a-chain). HLA-DR and TR (CD71) on CD4' and CDS' cells was observed at six but not at three days of culture. Moreover. this effect was achieved at drug concentrations which caused at least XO% inhibition of cell proliferation: lower concentrations. which produced <70% inhibition of DNA synthesis. did not suppress actlvation marker expression.
Despite these similarities in the effects of the three agents. marked differences In potency were recorded. FK 506 proved highly effective in inhibiting cell proliferation at approximately I nM. whilse MPA and MZB were 100-and IOOOO-foid less potent. Our data also confirm the distinct modes of action of FK 506 on the one hand and MPA and MZB on the other. FK 506 has been shown to inhtbit selectively the activation and proliferation of T cells stimulated via the T cell receptor/CD3 pathway:·2~. 26 Following binding of FK 506 to its intracellular. cytosolic receptor FK 506 binding protein (FKBP: predominant member FKBP-12). the FK 506-FKBP-complex binds to the calciumactivated phosphatase calcineurin. 27 Current thinking is that FK 506 may block dephosphorylation of the cytosolic component of the nuclear factor of activated T cells (NFAT)2H that is required for transcription of IL-2 mRNA.
Here we have extended our previous observations 24 • 29 that FK 506 inhibits activation molecule expression on OKT3 stimulated or alloactivated human Iymphocvtes. Thus. in the present study. using two-colour immunoftuorescence staining. we have shown that FK 506 inhibits lL-2R. HLA-DR and TR on both CD4 + and CD8' alloactivated T cells. We could not confirm an earlier report by Kino el al."~ that FK 506 inhibited IL-2R (CD25) more markedly on CDH' than on alloactivated CD4+ cells.
The antiproliferative effects of MFA and MZB differ distinctly from those of FK 506. Both former drugs are purine biosynthesis inhibitors. It has been reported that Immunosuppressive doses of MPA do not deplete lymphocytes and may have no effect on DNA synthesis In nonlymphoid tissues. such as gut epithelium or on most bone marrow progenitor cells.'" We have observed that neither MPA nor MZB affects Con A-induced T cell cvtokine gene expressIOn ([L-2. IL-4. IFN-"/ or lL-IO) (data not shown). Little previous data arc available concermng the effects of MPA or MZB on cytokines. Turka III al. l ? however. recently reported failure of MZB to inhibit phorbol mynstate acetate (PMA) + ionomycin-induced human T celllL-2 gene expression or cell surface 55 kD IL-2R expressIOn. In the latter instance. the anugen was studied after T cells were stimulated with PMA + ionomycin + antl-CD28. a much more powerful stimulus than the alloantigen used in the present study. This difference In strength of stimulus may explain the apparent discrepancy between the two studies.
Advances in our understanding of events underlying T cell activation have helped pmpomt slles of actlon of immunosuppressive drugs and aided in the design of new drug combination therapies. [n this study. combination of a suboptimal concentration of FK 506 with either MP A or MZB was found to inhibit cell proliferation at approximately the level seen with tenfold higher concentrations of FK 506. The apparent selectively of MP A and MZB for lymphoid T cells in vivo suggests that use of FK 506 together with either MP A or MZB may be useful for the immunosuppressive therapy of human allograft rejection. Indeed. Sollinger et al. 21 reported recently on the efficacy and safety of MPA (RS-61443) in combination with low doses of CsA and prednisone in clinical renal transplantation. Furthermore. like FK 506. neither MP A nor MZB has been reported to affect the bone marrow at immunosuppressive doses.1 6 .1 7 a possible advantage over azathioprine in minimizing the toxicity of drug combination therapy.
